Use of abciximab during infrainguinal peripheral vascular interventions: initial experience

Radiology. 2003 Jun;227(3):657-61. doi: 10.1148/radiol.2273020130.

Abstract

Purpose: To investigate the use of abciximab as an adjunct during infrainguinal angioplasty.

Materials and methods: Abciximab was used in conjunction with recanalization techniques and angioplasty to treat stenoses or occlusions in 16 patients: 10 patients had high-grade stenoses or occlusions longer than 5 cm in the superficial femoral artery and popliteal artery, and six patients had stenoses or occlusions below the popliteal artery. All patients received a bolus of heparin after arterial access was achieved. Abciximab was administered by means of a weight-base nomogram that consisted of an initial bolus followed by an overnight infusion. Technical success was defined as a less than 30% residual stenosis after angioplasty. Patients were carefully followed up for possible postprocedural complications. Platelet counts were monitored for 24 hours.

Results: Technical success was achieved in 15 (94%) of 16 patients. One occlusion of the superficial femoral artery could not be crossed. There was a mean postprocedural increase of 0.23 in the ankle-brachial index. There was no significant effect on platelet count. Two minor complications occurred. One major complication occurred; this was a groin hematoma, which required a blood transfusion.

Conclusion: The use of abciximab as an adjunct during complex infrainguinal arterial interventions appears promising, on the basis of initial experience.

MeSH terms

  • Abciximab
  • Angioplasty, Balloon*
  • Antibodies, Monoclonal / therapeutic use*
  • Arterial Occlusive Diseases / therapy*
  • Constriction, Pathologic / therapy
  • Female
  • Femoral Artery
  • Heparin / therapeutic use
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Male
  • Middle Aged
  • Peripheral Vascular Diseases / therapy*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Popliteal Artery

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Heparin
  • Abciximab